Kwan Ho Tang
Overview
Explore the profile of Kwan Ho Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farouk Sait S, Tang K, Angus S, Brown R, Sun D, Xie X, et al.
Proc Natl Acad Sci U S A
. 2025 Jan;
122(1):e2407745121.
PMID: 39793045
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within preexisting benign lesions called...
2.
Franca G, Baron M, King B, Bossowski J, Bjornberg A, Pour M, et al.
Nature
. 2024 Jul;
631(8022):876-883.
PMID: 38987605
Advancements in precision oncology over the past decades have led to new therapeutic interventions, but the efficacy of such treatments is generally limited by an adaptive process that fosters drug...
3.
Chang C, Jen J, Jiang S, Sayad A, Mer A, Brown K, et al.
Cancer Discov
. 2021 Dec;
12(4):1022-1045.
PMID: 34911733
Significance: DTPs are implicated in resistance to anticancer therapies, but their ontogeny and vulnerabilities remain unclear. We find that HER2 TKI-DTPs emerge from stochastically arising primed cells ("pre-DTPs") that engage...
4.
Han H, Li S, Chen T, Fitzgerald M, Liu S, Peng C, et al.
Cancer Res
. 2021 Aug;
81(20):5311-5324.
PMID: 34380634
No targeted treatments are currently approved for exon 20 insertion-mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor...
5.
Tang K, Li S, Khodadadi-Jamayran A, Jen J, Han H, Guidry K, et al.
Cancer Discov
. 2021 Aug;
12(1):47-61.
PMID: 34353854
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is...
6.
Fedele C, Li S, Teng K, Foster C, Peng D, Ran H, et al.
J Exp Med
. 2020 Oct;
218(1).
PMID: 33045063
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react with Cys-12 (G12C-Is). Using new...
7.
Hussain A, Voisin V, Poon S, Karamboulas C, Bui N, Meens J, et al.
J Exp Med
. 2020 May;
217(8).
PMID: 32434219
Recent studies indicate that cancer-associated fibroblasts (CAFs) are phenotypically and functionally heterogeneous. However, little is known about CAF subtypes, the roles they play in cancer progression, and molecular mediators of...
8.
Diskin B, Adam S, Cassini M, Sanchez G, Liria M, Aykut B, et al.
Nat Immunol
. 2020 Mar;
21(4):442-454.
PMID: 32152508
Programmed cell death protein 1 (PD-1) ligation delimits immunogenic responses in T cells. However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells are uncertain....
9.
Leung C, Tong M, Chung K, Zhou L, Che N, Tang K, et al.
Hepatology
. 2019 Oct;
72(1):155-168.
PMID: 31610028
Background And Aims: The survival benefit of sorafenib for patients with hepatocellular carcinoma (HCC) is unsatisfactory due to the development of adaptive resistance. Increasing evidence has demonstrated that drug resistance...
10.
Sinha A, Hussain A, Ignatchenko V, Ignatchenko A, Tang K, Ho V, et al.
Cell Syst
. 2019 Apr;
8(4):345-351.e4.
PMID: 30981729
High-grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy...